The whole-exome sequencing (WES) identified no potentially actionable alteration in the tumor sample but found five alterations all with allele frequency over 90%, including <i>TP53</i> p.R273H, <i>MYH8</i> p.Q1814K, <i>SLC17A6</i> p.W505L, <i>PTPN5</i> p.M40I, and <i>RB1</i> p.L267X. The gene discussed is SLC17A6; the disease is neoplasm.